Azione BDTX BLACK DIAMOND THERAPEUTICS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Black Diamond Therapeutics, Inc. OTC Markets

Azioni

BDTX

US09203E1055

Tempo reale stimato Cboe BZX
Altri mercati azionari
 20:13:33 04/06/2024 		Variaz. 5gg Var. 1 gen.
4,825 USD 0,00% Grafico intraday di Black Diamond Therapeutics, Inc. 0,00% 0,00%
01/06 Black Diamond Therapeutics, Inc. presenta i promettenti dati clinici di Bdtx-1535 nei pazienti con glioblastoma ricorrente al meeting annuale della Società Americana di Oncologia Clinica (Asco) del 2024 CI
16/05 BLACK DIAMOND THERAPEUTICS, INC. : da HC Wainwright è Buy ZM

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond: Q1 Earnings Snapshot
Black Diamond Therapeutics : Reports First Quarter 2024 Financial Results and Provides Corporate Update - Form 8-K
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes
Black Diamond Therapeutics Announces Changes to Board of Directors
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond: Q4 Earnings Snapshot
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione BDTX
  4. Azione BDTX
  5. Notizie Black Diamond Therapeutics, Inc.
  6. Altre lingue
-40% Proroga eccezionale: i nostri abbonamenti ti guidano verso i migliori investimenti di domani.
APPROFITTANE ORA